Form 4: GeneDx Holdings Corp. CEO Katherine Stueland Reports Stock Transactions

Katherine Stueland, CEO of GeneDx Holdings Corp., reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Summary

• On March 16, 2024, Katherine Stueland, CEO of GeneDx Holdings Corp., vested 18,750 Class A Common Stock shares through the settlement of restricted stock units (RSUs).
• These RSUs vested in quarterly installments starting March 16, 2023, over a four-year period.
• On March 18, 2024, Stueland sold 8,559 shares of Class A Common Stock at a weighted average price of $10.5925 per share.
• The sale was executed to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Stueland directly owns 66,698 shares of Class A Common Stock.
• Stueland also holds 225,000 derivative securities in the form of Restricted Stock Units.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an insider. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives and directors.

Stakeholder Impact

• The sale of shares by the CEO could have a minor impact on shareholder sentiment, but is likely insignificant given the context of covering tax obligations.

Key Dates